Overview of Obrex

Property	Description
Active ingredient	Phendimetrazine Tartrate
Form	Tablet (Immediate-release), Capsule (Extended-release)
Pharmacological class	Sympathomimetic Amine, Anorectic Agent
General purpose	Short-term aid for weight reduction in exogenous obesity
Origin	Synthetic Phenylalkylamine

Obrex is a prescription-only medication containing the active component Phendimetrazine Tartrate, a substance utilized primarily for short-term support in managing exogenous obesity. The medication is classified as an anorectic agent—meaning it works by suppressing the appetite—and is used as an adjunctive component of a comprehensive weight reduction program.

What Type of Medicine is Obrex? (Identity and Classification)

Obrex belongs to the Sympathomimetic Amine pharmacological class, chemically defined as a synthetic phenylalkylamine. This class of drugs affects the central nervous system by influencing chemical messengers, leading to reduced hunger. Phendimetrazine Tartrate is indicated as an appetite suppressant for short-term use in the management of exogenous obesity in conjunction with diet. This classification means the medicine is recognized to help curb appetite as part of a weight-loss plan.

The active ingredient functions as a prodrug, converting inside the body to the active compound, phenmetrazine, which mediates the primary therapeutic effect. Phendimetrazine Tartrate is a Schedule III controlled substance.

Composition and Available Forms of Phendimetrazine

The drug is a single-active-ingredient product containing the stable salt Phendimetrazine Tartrate, delivered via oral administration. The medication is available in two distinct dosage forms: the immediate-release tablet and the extended-release capsule. This therapeutic flexibility, offering either rapid absorption or a gradual effect over several hours, is a key factor in its clinical application compared to other anorectics.

General Purpose: Supporting Weight Reduction

The primary general purpose of Obrex is to act as a short-term aid in the treatment of obesity. By targeting the brain centers that regulate hunger, the medicine reduces the patient's drive to eat and provides a mild central nervous system stimulation. This mechanism is intended to support adherence to a necessary reduced-calorie diet, thereby facilitating overall weight reduction.

Regulatory References

What side effects are possible with Obrex?

Possible Side Effects and Safety Information

The safety profile of Obrex (Phendimetrazine Tartrate) is officially documented by regulatory authorities, classifying potential adverse reactions by body system and defining strict use limitations. The most commonly reported adverse reactions, though often without specific frequency percentages in U.S. labeling, involve the Cardiovascular System (e.g., palpitation, tachycardia, elevated blood pressure) and the Central Nervous System (e.g., insomnia, restlessness, headache). Gastrointestinal effects like dry mouth and constipation are also frequently noted.

Serious and Exposure-Related Safety Concerns

The regulatory labeling reports rare but clinically serious adverse reactions, including Primary Pulmonary Hypertension (PPH) and Valvular Heart Disease. The risk of psychological dependence and the development of tolerance (diminished effect) are safety patterns associated with prolonged administration of this medication. Upon abrupt cessation following high-dose use, severe withdrawal effects may occur.

Safety Restrictions

Use of Obrex is contraindicated by official labels in patients with specific pre-existing conditions, including advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, and glaucoma. It is also prohibited in patients with a history of agitated states or drug abuse, or concurrent use with or within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI). Safety has not been established for children under 12 years of age, and dosage selection for older adults requires specific caution due to reduced clearance.

Overdose and Emergency Response

Overdosage with Phendimetrazine Tartrate is documented in official prescribing information as presenting with specific patterns of systemic toxicity, primarily affecting the central nervous system (CNS) and cardiovascular system.

Documented Manifestations and Severe Outcomes

Acute overdose may manifest as unusual restlessness, confusion, panic states, or hallucinations. Cardiovascular signs include arrhythmias, hypertension, or hypotension, which can progress to circulatory collapse. Gastrointestinal symptoms like nausea and abdominal cramps are also noted. In severe cases, overdose can lead to convulsions, coma, and death. Furthermore, chronic intoxication is officially documented to result in severe adverse outcomes, including psychosis.

Required Emergency Actions

The regulatory guidance requires individuals to seek immediate medical attention for any serious symptoms, specifically including passing out or trouble breathing. Management of overdosage is defined as largely symptomatic and supportive, and no specific antidote is known or routinely utilized. Due to the major route of elimination being the kidneys, the official labeling notes that the risk of toxic reactions may be greater in patients with impaired renal function.

Therapeutic Uses of Obrex

Phendimetrazine Tartrate is relevant in contexts involving heightened systemic burden related to weight management.

The medication is used as a short-term adjunctive treatment for conditions involving significant excess body weight. This primarily includes exogenous obesity and conditions where functional stability becomes affected by excess weight, such as when controlled hypertension or high cholesterol are present. This medicine is commonly used to help manage adults and older adolescents who meet specific weight criteria when non-drug reduction methods alone have not achieved adequate results.

The medication is applied across domains where additional symptomatic support is needed to manage symptoms related to physical discomfort, specifically persistent and excessive hunger sensations. By contributing to improved comfort during the necessary period of strict caloric restriction, this support assists with maintaining functional stability during demanding dietary phases.

“Applied across domains where additional symptomatic support is needed, the medication assists with maintaining functional stability during demanding dietary phases.”

Quick Fact: Symptomatic Support Focus This medication is commonly used to help patients manage symptoms that interfere with daily comfort, specifically the strong drive to eat that challenges adherence to necessary calorie restrictions.

Regulatory References

DailyMed NIH Labeling for PHENDIMETRAZINE TARTRATE

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Obrex (Phendimetrazine Tartrate) — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Patients with exogenous obesity meeting specific initial BMI criteria (ge 30 kg/m^2, or ge 27 kg/m^2 with risk factors) [DailyMed].
Populations for whom use is not recommended (if applicable)	Patients with a known heart murmur or valvular heart disease; patients who have developed tolerance to the anorectic effect [FDA Accessdata].
Populations for whom use is contraindicated	Patients with a history of cardiovascular disease (e.g., stroke, uncontrolled hypertension, symptomatic CVD), hyperthyroidism, glaucoma, or drug abuse [DailyMed].
Age-related eligibility rules	Adults and Adolescents 17 years and older (Extended-release form). Use is not recommended for children under 17 (ER) or under 12 (IR) [FDA Accessdata].
Condition-specific eligibility rules	Mild Hypertension: Use with caution (Contraindicated in moderate/severe). Renal Impairment: Use with caution due to drug elimination via the kidney [FDA Accessdata].
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Contraindicated (Weight loss offers no benefit and may result in fetal harm). Nursing/Breastfeeding: Contraindicated/Not Recommended [FDA Accessdata].
Eligibility-related restrictions	Use is limited to short-term therapy (a few weeks). Contraindicated during or within 14 days following administration of a Monoamine Oxidase Inhibitor (MAOI) [DailyMed].

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification
Eligibility severity classification (as defined in official documents)	Contraindicated (Absolute exclusion) for severe cardiovascular, endocrine, and CNS history conditions. Not Recommended (Strong caution) for certain age groups, known valvular disease, and in cases of tolerance.
Regulatory basis (EMA / FDA / etc.)	U.S. Food and Drug Administration (FDA) Prescribing Information / DailyMed.
Eligibility-context constraints (as defined in official documents)	Must be used as a short-term adjunct in a caloric restriction regimen; use is dependent on meeting specific BMI criteria.

Resulting Eligibility Structure

Official Eligibility Statements:

The medicine is contraindicated in patients with a history of cardiovascular disease, hyperthyroidism, glaucoma, or drug abuse.
Use is contraindicated in women who are pregnant or nursing.
The medicine is not recommended for use in pediatric patients under 17 years of age.
Use is contraindicated within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI).
The drug is indicated only for individuals who meet specific BMI criteria for short-term use (a few weeks).

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Obrex by establishing strict, label-based contraindications that prioritize cardiovascular and central nervous system integrity, alongside age-related exclusions for children and young adolescents. The documents further enforce a conditional eligibility based on specific initial body mass index thresholds and the mandatory limitation of the therapy to a short-term duration.

What should I know about interactions with other medicines?

Obrex (Phendimetrazine Tartrate) is associated with several officially documented interaction patterns, primarily driven by its sympathomimetic amine classification.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, posing a risk of hypertensive crisis. A mandatory separation period of 14 days is required between discontinuing an MAOI and initiating Obrex. Furthermore, use is prohibited with other anorectic agents, encompassing prescription medications, over-the-counter preparations, and certain herbal products, due to the recognized potential for serious cardiac issues. These restrictions reflect the product's official pharmacodynamic reinforcement domain.

Regarding other medicinal products, Obrex may decrease the hypotensive effect of Adrenergic Neuron Blocking Drugs. The requirements for Insulin and Oral Hypoglycemic Medications in diabetic patients may also be altered, reflecting a change associated with the drug's use and the necessary dietary regimen.

The concomitant use of alcohol is restricted by regulatory labeling due to the potential for an adverse drug reaction. Finally, renal impairment is noted as a population-specific consideration; as the medicine is excreted through the urine, patients with impaired kidney function may experience increased exposure due to reduced clearance. No specific interactions mediated by CYP450 enzymes or major drug transporters are explicitly detailed in official regulatory prescribing information.

Mechanism of Action

Central Neurotransmitter Release and Modulation

Obrex’s mechanism is executed via its active metabolite, phenmetrazine, an indirect sympathomimetic. This compound engages the Norepinephrine Transporter (NET) and the Dopamine Transporter (DAT), reversing their normal reuptake function through a releasing agent mechanism. This action facilitates the efflux of stored norepinephrine and dopamine into the synaptic cleft, significantly modulating signaling across monoamine-dependent neural pathways.

Hypothalamic Appetite Pathway Adjustment

The resulting elevated concentrations of norepinephrine and dopamine primarily affect regulatory centers in the hypothalamus. Within these pathways, the monoamines activate receptors associated with satiety regulation and attenuate signaling from pathways associated with hunger. This mechanism results in an altered physiological drive for energy consumption due to the adjustment of activity within this core regulatory system.

Systemic Sympathetic Tone Engagement

This mechanism is non-selective and leads to a generalized increase in Sympathetic Nervous System (SNS) outflow throughout the body. This involves the activation of peripheral alpha- and beta-adrenergic receptors. The engagement of the autonomic system leads to physiological consequences, including changes in heart rate and blood pressure, characteristic of the drug’s systemic mechanism.

Dosage and Administration Information

How to Use Obrex (Phendimetrazine Tartrate)

Obrex (Phendimetrazine Tartrate) is administered exclusively by the oral route, with administration instructions varying based on the specific dosage form. The medication is available as both an Immediate-Release (IR) Tablet and an Extended-Release (ER) Capsule.

Standard Dosing and Frequency

Administration Aspect	Immediate-Release (IR) Tablet	Extended-Release (ER) Capsule
Typical Dose	35 mg, two or three times daily	105 mg, once daily
Timing	Taken one hour before meals	Taken 30 to 60 minutes before the morning meal
Maximum Dose	Not to exceed 70 mg three times a day	105 mg once daily

This medication is designated for short-term adjunctive use, a period typically limited to a few weeks. The continuation of therapy is not open-ended: treatment must be discontinued if a minimum weight loss (e.g., 4 pounds) is not achieved within the first four weeks, or if tolerance to the appetite-suppressant effect develops.

Administration and Population-Specific Rules

The ER capsule must be swallowed whole and must not be crushed, broken, or chewed to preserve its intended release pattern. In terms of age restrictions, the safety and effectiveness of Obrex are not established for pediatric patients under the age of 17 or 18, depending on the specific formulation. Dose selection for older adults must be cautious, typically beginning at the low end of the dosing range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Obrex

This section describes the type of scientific data that exists for Obrex (phendimetrazine tartrate) and the scope of the outcomes that researchers have monitored. This information describes group patterns, not personal outcomes.

Evidence for Short-Term Use in Exogenous Obesity

Research examined Obrex for short-term use in exogenous obesity. This evidence comes mainly from short-term clinical trials, often randomized and controlled, where researchers compared Obrex alongside a reduced-calorie diet against a placebo alongside a reduced-calorie diet.

Research primarily examined outcomes related to systemic or functional imbalance, specifically weight change, including the total change in body weight from the start of the study and the rate of weight change over the observation period. Clinical trials monitored measured average weight change in groups receiving Obrex alongside diet, compared to those receiving placebo alongside diet, during the short study period.

Findings indicate that the difference in observed weight change between Obrex-treated patients and placebo-treated patients was observed in some studies to be relatively small. Findings indicate that the weight change reported varied considerably among the different trials reviewed, suggesting that non-drug factors such as the specific diet or the population being studied may influence the measurements.

Duration of Evidence and Known Limitations

Trial designs typically required adult subjects with obesity to meet specific criteria, such as having a Body Mass Index (BMI) of 30 kg/m² or higher, or a lower BMI with weight-related risk factors. The studies cited are restricted to follow-up durations that were limited, typically lasting only a few weeks.

Research describes patterns where the appetite-suppressing effect appears to decrease or develop tolerance within a few weeks of use. This suggests that the measured effect may decrease over time. Furthermore, epidemiological studies have explored the risk of pulmonary hypertension, where the use of anorectic agents, including Obrex, was associated with an increased frequency of this event.

Areas Where Research Remains Incomplete

There is limited information for long-term outcomes regarding sustained weight management. The available studies do not provide sufficient data on the durability of weight change after the short-term treatment period is completed. Comparative evidence is lacking in formal studies concerning how the measurements of Obrex compare to those of other FDA-approved weight loss medicines.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Obrex (FAQ)

Q: Will Obrex make me feel tired right away?

A: Official documents describe Obrex as a sympathomimetic amine, which functions as a stimulant. Common central nervous system-related side effects include restlessness, overstimulation, and insomnia rather than immediate tiredness. However, regulatory warnings note that extreme fatigue and mental depression may result if the medicine is abruptly stopped after prolonged, high-dose use.

Q: How long does it usually take to feel the effects of Obrex?

A: Official pharmacokinetic information indicates that Obrex's active ingredient is described as being absorbed quickly. For the immediate-release (IR) tablet form, peak plasma levels—the time of maximum concentration—occur within 1 to 3 hours after the dose is taken. Based on this data, the effects are generally observed within this short timeframe.

Q: What happens if a dose of Obrex is missed?

A: General patient guidance for this type of medication advises that a missed dose should be skipped if it is almost time for the next scheduled dose. Regulatory information describes that a double dose should not be taken to compensate for a missed one. Specific instructions for a missed dose must be obtained from a prescribing healthcare professional.

Q: Are there any specific foods to avoid while using Obrex?

A: The most restrictive regulatory labeling concerns the use of alcohol, which is prohibited due to the potential for adverse drug reactions. While Obrex is intended to be used with a reduced-calorie diet for weight management, official labeling does not universally restrict specific non-alcoholic foods. The comprehensive dietary plan is a required component of therapy and is outlined by the patient’s healthcare team.

Q: Does Obrex have a warning about driving or operating machinery?

A: Yes, the official prescribing information includes a warning about operating machinery. Because of its stimulating and central nervous system effects, Obrex may impair a patient’s ability to safely engage in activities such as driving a motor vehicle. Official documents state that patients are cautioned about this potential impairment.

Q: Are the side effects of Obrex permanent?

A: Official regulatory documents document rare but serious adverse effects like Primary Pulmonary Hypertension and Valvular Heart Disease, which are associated with this drug class. Because Obrex is only approved for short-term use, official guidance emphasizes that the risks of these conditions should be carefully evaluated during the treatment period.

Q: Can Obrex be taken with antacids?

A: Regulatory drug interaction databases indicate that combining Phendimetrazine, the active component of Obrex, with certain antacids should be approached with caution. Specific antacids containing aluminum compounds may lead to an increased concentration of Phendimetrazine in the bloodstream. Assessment by a healthcare professional is necessary to determine if this combination is appropriate based on the patient's full medication list.

Q: Does taking Obrex require regular blood tests?

A: Official drug precautions state that a doctor should periodically monitor a patient's progress to ensure the medicine is working properly and to check for potential unwanted effects. Regulatory-cited information notes that blood tests may be needed for monitoring purposes, particularly for patients with coexisting conditions like diabetes.

Q: Where can I find the most reliable information about Obrex research?

A: Reliable, evidence-based summaries of Obrex clinical trial data and research are found in authoritative government sources. These include the official prescribing information published by agencies like the U.S. Food and Drug Administration (FDA) (via DailyMed) and the drug pages provided by the National Institutes of Health (NIH) (via MedlinePlus).

Q: Why is Obrex given a 'Black Box Warning' (if applicable)?

A: While the explicit term 'Black Box Warning' may not be uniformly used across all official documents, the regulatory label contains prominent warnings about serious risks. These warnings highlight the association of this drug class with rare but clinically significant adverse reactions, including the development of Pulmonary Hypertension and Valvular Heart Disease.

Q: What is the difference between Obrex and a generic version (if one exists)?

A: The FDA classifies Phendimetrazine Tartrate generic products as having therapeutic equivalence to the brand-name drug Obrex. This classification means that generic versions are expected to have the same clinical effect and safety profile when substituted for the brand. The equivalence is formally listed in the FDA's 'Orange Book' for consumers and professionals.

Q: Does Obrex affect fertility?

A: Official documents state that specific studies to evaluate the effects of Phendimetrazine Tartrate on fertility have not been performed. Official documents also state that the safe use of the drug in women who are pregnant or who may become pregnant has not been established.

How should Obrex be stored and disposed of?

The storage and disposal of Obrex (Phendimetrazine Tartrate) must strictly follow regulatory mandates, reflecting its classification as a Schedule III controlled substance.

Storage Requirements

Obrex must be stored at Controlled Room Temperature between 20°C to 25°C (68°F to 77°F). The container must be tight and light-resistant, and the medicine must be protected from moisture and heat. Due to its classification, the product should be secured in a locked-up place and kept out of the reach of children to prevent theft and misuse.

Disposal Instructions

Disposal of unused or expired Obrex requires using drug take-back programs or following specific governmental procedures for controlled substances. Patients should not keep unneeded medication and must consult a healthcare professional regarding proper disposal to comply with federal regulations.

Obrex